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Abstract
Background: Psychotic major depression is a clinical subtype of major depressive disorder. A number of clinical studies 
have demonstrated the efficacy of the combination of an antidepressant (for example, a tricyclic antidepressant or 
selective serotonin reuptake inhibitor (SSRI)) and an atypical antipsychotic or electroconvulsive therapy (ECT) in 
treating psychotic major depression. In several studies, monotherapy of SSRIs such as fluvoxamine has been shown to 
be effective in the treatment of psychotic major depression.
Methods: We report on a 36-year-old Japanese woman in whom fluvoxamine (a SSRI with sigma-1 receptor agonist) 
and sertraline (a SSRI with sigma-1 receptor antagonist) showed the opposite effects on psychotic symptoms in the 
treatment of psychotic major depression.
Results: Symptoms of depression and psychosis in the patient who was non-respondent to antipsychotic drugs 
improved after fluvoxamine monotherapy. At 3 years later, a switch to sertraline from fluvoxamine dramatically 
worsened the psychotic symptoms in the patient. Then, a switch back to fluvoxamine from sertraline improved these 
symptoms 1 week after fluvoxamine treatment.
Conclusion: Doctors should consider the monotherapy of sigma-1 receptor agonist fluvoxamine as an alternative 
approach to treating psychotic major depression.
Background
Psychotic major depression is a clinical subtype of major
depressive disorder and is characterized by psychosis
accompanied by relatively severe depressive symptoms.
Unfortunately, psychotic major depression frequently
proves difficult to treat. A number of clinical studies have
demonstrated the efficacy of the combination of an anti-
depressant (for example, a tricyclic antidepressant or
selective serotonin reuptake inhibitor (SSRI)) and an
atypical antipsychotic or electroconvulsive therapy (ECT)
in treating psychotic major depression. In some cases, the
clinician or patient may prefer to avoid antipsychotic
drugs altogether because of the risk of extrapyramidal
side effects in patients with psychotic major depression
treated with these drugs [1-3].
SSRI fluvoxamine monotherapy has been reported to
be effective against both the psychotic and depressive
symptoms of this disorder [4-8], whereas sertraline
appears to have a lower efficacy [9], suggesting that each
SSRI might have a different spectrum of effectiveness in
the treatment of psychotic major depression [10-12]. The
precise mechanisms underlying the difference in efficacy
for these two SSRIs are currently unknown. Here, we
report a case in which fluvoxamine and sertraline showed
marked opposite effects in the treatment of psychotic
major depression.
Case report
The patient was a 36-year-old Japanese woman who was
diagnosed with psychotic major depression (F-32.3:
severe depressive episode with psychotic symptoms)
according to International Classification of Disease, 10th
edition (ICD-10) criteria. The duration of her illness was
approximately 15 years. Before admission to our clinic,
she was treated with fluvoxamine (150 mg) and risperi-
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done (4 mg) for about 1 year, and her symptoms were
recovered. Then, she was admitted to the clinic due to
delusions of persecution, including 'Everybody hopes that
I return to the home from day care', 'The persons at day
care are annoying me. I am troubling other persons', 'I do
not like eyes of the persons who meet me at the return
from day care. A man comes after me on the way of com-
ing to the clinic', and depression. Risperidone (4 mg) was
also added to the fluvoxamine (100 mg) treatment, but
there no therapeutic effects were observed with respect
to these delusions. The antipsychotic drug perospirone
(12-24 mg) was then added, but it also showed no effect
on the delusions. The fluvoxamine was therefore
increased to 150 mg, and her delusions began to gradu-
ally decrease and finally disappeared completely. After
recovery, risperidone treatment was stopped. Treatment
with fluvoxamine (150 mg) monotherapy was main-
tained, and her condition remained good.
At 2 years after the disappearance of the delusions, the
patient began overeating and oversleeping, as well as
experiencing premenstrual syndrome. The Diagnostic
and Statistical Manual of Mental Disorders, fourth edi-
tion (DSM-IV) criteria for atypical features include mood
reactivity in addition to two of the following symptoms:
overeating, oversleeping, severe fatigue or leaden paraly-
sis, and a history of rejection sensitivity. Therefore, flu-
voxamine (150 mg) was stopped because the diagnosis of
atypical depression was doubted, and the patient was
changed to another SSRI, sertraline (75 mg), as sertraline
has been shown to be effective in the treatment of atypi-
cal depression and premenstrual syndrome [13-15]. At 3
days after the switch to sertraline, the patient suffered
from several delusions such as 'Neighbors kick the wall of
the house at home', 'They talk about me on the TV news',
and 'The environment where I live now is bad'. In addi-
tion, she experienced cenestopathy such as 'I always think
that there are chopsticks in the hole of my nose'. The ser-
traline was therefore stopped and was changed to fluvox-
amine (150 mg). A week after fluvoxamine monotherapy
treatment was given, the above symptoms and experi-
ences rapidly disappeared.
Discussion
Here we report a case showing the opposite effects of flu-
voxamine and sertraline in a female patient with psy-
chotic major depression that was non-respondent to
antipsychotics. In this case, fluvoxamine monotherapy
was effective in the treatment of psychotic major depres-
sion, and the switch to sertraline worsened the psychotic
symptoms in the patient. The mechanisms underlying the
opposite effects of these two SSRIs on the symptoms of a
patient with psychotic major depression are currently
unclear. This case suggests that fluvoxamine is clinically
effective in the treatment of psychotic major depression,
but sertraline may not be clinically useful for psychotic
major depression although a further detailed study is nec-
essary. It is thus likely that doctors should treat very care-
fully for the treatment of psychotic major depression
using SSRI monotherapy.
One possible mechanism may be due to the difference
in the action of these SSRIs at the endoplasmic reticulum
protein sigma-1 receptors. Several pieces of evidence sug-
gest that sigma-1 receptors play a role in the pathophysi-
ology of major depression and in the active mechanisms
of some antidepressants [16-20]. The inhibition constants
(Ki) of fluvoxamine and sertraline at sigma-1 receptors
are 36 nM and 57 nM, respectively [21]. Some recent
studies have suggested that fluvoxamine is a potent ago-
n i s t  a t  s i gm a - 1  r ec e p t o r s,  w h e r eas  se rt r a l i n e  m a y  be  a
sigma-1 receptor antagonist [18,19,22-24]. A positron
emission tomography study demonstrated that fluvoxam-
ine binds to sigma-1 receptors in the intact human brain
at therapeutic doses [25], suggesting that sigma-1 recep-
tors are involved in the active mechanisms of fluvoxam-
ine [19]. Interestingly, the addition of haloperidol (a
potent sigma-1 receptor antagonist) has been found to
r e d u c e  t h e  r e s p o n s e  r a t e  t o  f l u v o x a m i n e  f r o m  6 9 %  t o
45%, suggesting that haloperidol might antagonize the
sigma-1 receptor activity of fluvoxamine [26]. Based on
all these findings, it has been hypothesized that the
sigma-1 receptors may be implicated in the efficacy of
fluvoxamine for psychotic depression [7,8,10-12]. It
seems that serotonin reuptake inhibition as well as sigma-
1 receptor agonism may be involved in the active mecha-
nism of fluvoxamine, since paroxetine (no affinity at
sigma-1 receptors) has a lesser effect in psychotic major
depression [27]. Although this case study does not clarify
whether sigma-1 receptors are involved in the active
mechanism of fluvoxamine, it is likely that the difference
in the pharmacological actions (agonist or antagonist) of
the two SSRIs at the sigma-1 receptors may have been
related to the mechanisms of the opposite effects of the
two SSRIs in this case. Thus, it seems that the antagonism
of sigma-1 receptors by sertraline may be involved in the
recurrence of psychotic symptoms in this case, although a
further detailed study is necessary.
Another possibility is due to the potent inhibition (Ki =
22 nM for sertraline, Ki = 16,790 nM for fluvoxamine) of
dopamine transporter by sertraline [28]. It is suggested
that the relative potency of sertraline for dopamine trans-
porter inhibition might differentiate its psychopharma-
cology from that of other SSRIs [29]. It is therefore
possible that activation of the dopaminergic system by
the inhibition of dopamine transporter may be involved
in the mechanism of unwanted effects (deterioration of
psychosis) of sertarline in this case, although further
study is necessary.Kishimoto et al. Annals of General Psychiatry 2010, 9:23
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Conclusions
This case suggests that the sigma-1 receptor agonist flu-
voxamine could be an alternative approach in treating
psychotic major depression. More detailed randomized,
double-blind studies should be performed to clarify the
role of sigma-1 receptors in the efficacy of fluvoxamine
for psychotic major depression.
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